Suche
Mein Konto
Digital early detection of MCI: New study shows promising results
The Re.cogni.ze study presents the first results on the digital early detection of the slight cognitive disorder (MCI) for all medical care levels. The NeotivCare app offers added value compared to conventional methods and is easy to use. The study shows high patient satisfaction and adherence as well as new opportunities through early diagnosis. The app serves the clinical assessment of cognitive functions and provides a meaningful letter of findings for further treatment. Find out more at www.neotiv-care.com/Medizinische-fachperspref.
Digital early detection of MCI: New study shows promising results
Digital early detection of mild cognitive disorder (MCI): A groundbreaking study shows encouraging results
Magdeburg/Philadelphia, July 29, 2024 - At the Alzheimer’s Association International Conference (AAIC) in Philadelphia, exciting results of a new study on the digital early detection of mild cognitive disorder (MCI) were presented. The re.cogni.ze study initiated by Roche and in cooperation with the company Neotiv has shown that the neotive care app is suitable for the early detection of MCI at all medical care levels and offers added value compared to conventional procedures.
The Re.Cogni.ze study, the largest study of this kind in Germany, was carried out over a period of 22 months and comprised 27 resident neurologists and psychiatrists, 13 general practitioners and three memorial outpatients. A total of 765 patients were included in the study.
The patients received the neotivecare app for self-monitoring of memory problems from their treating doctors. Over a period of twelve weeks, the patients carried out weekly tests and self -assessment with the app. At the end of the test period, the app created a letter of finding that served as the basis for the findings with the doctor.
The results of the study are promising: 93 percent of the patients who had activated the NeotivCare app showed a high level of adherence. Patient satisfaction was also high, 67.6 percent reported added value through the app and 51 percent stated that their concerns had decreased by using the app. The doctors surveyed also showed greater satisfaction with the app compared to conventional tests.
The importance of the study is that an early diagnosis of MCI is crucial for intervention at Alzheimer's. The NeotivCare app enables low-threshold and effective early detection of MCI so that patients can be treated early.
The neotivcare app is a CE-identified medical device that contains three types of tests for evaluating cognitive functions. After completing the test period, the app automatically creates a letter of finding that provides the doctor important information about the patient's memory.
The results of this groundbreaking study offer new hope for the early detection of MCI and the treatment of Alzheimer's. The NeotivCare app could play an important role in the identification of patients who are affected by memory problems and need early diagnosis and treatment.
Further information on the NeotivCare app can be found on the company of the company.